J Korean Dent Sci.  2018 Dec;11(2):57-61. 10.5856/JKDS.2018.11.2.57.

Polydeoxyribonucleotide, as a Novel Approach for the Management of Medication-Related Osteonecrosis of the Jaw: A Preliminary Observational Study

• Jung J
• Lim HS
• Lee DW

• KMID: 2437342
• DOI: http://doi.org/10.5856/JKDS.2018.11.2.57

Abstract

PURPOSE
Polydeoxyribonucleotide (PDRN), consisting of a mixture of deoxyribonucleotide polymers, has been suggested to have anti-inflammatory effects and enhance angiogenesis as an adenosine A(2A) receptor agonist. The aim of this study was to report the effectiveness of PDRN as an adjuvant therapy after surgical debridement in MRONJ (medication-related osteonecrosis of the jaw) patients.
MATERIALS AND METHODS
Five patients (1 male, 4 females, age 65~79 years) who were diagnosed with MRONJ stage 2 or 3 underwent surgical debridement and PDRN mucosal injection. After surgical debridement, patients were subject to daily injection with 1 ml of PDRN around the surgical wound for 14 days. RESULT: The patients' symptoms gradually disappeared. The surgical wound uneventfully healed, and no recurrence was observed during the follow-up period.
CONCLUSION
Although further studies are required, the present study first describes the possibility of PDRN as a useful option for MRONJ treatment.

Keyword

Medication-related osteonecrosis of the jaw; Polydeoxyribonucleotide

MeSH Terms

Debridement
Female
Follow-Up Studies
Humans
Jaw*
Male
Observational Study*
Osteonecrosis*
Polymers
Receptor, Adenosine A2A
Recurrence
Wounds and Injuries
Polymers
Receptor, Adenosine A2A